title: No clinically important effects on intraocular pressure after short-term administration of sildenafil citrate (Viagra).
abstract: OBJECTIVE
  To assess the short-term effects of sildenafil citrate on intraocular pressure in healthy male volunteers and participants in clinical trials.
  
  
  METHODS
  Intraocular pressure and pupil diameter were measured in two placebo-controlled studies. Oral doses of sildenafil citrate (VIAGRA; Pfizer Inc, New York, New York) ranged from 10 mg to 150 mg.
  
  
  RESULTS
  No major changes in intraocular pressure or pupillometry were detected at any time (1.0-24 hours) after administration of sildenafil. Additionally, of 36 subjects with a medical history of increased intraocular pressure in the sildenafil safety database, none were reported to have a clinically significant increase of their intraocular pressure. During clinical trials, two glaucoma cases were listed as serious adverse events, but were not considered treatment related.
  
  
  CONCLUSIONS
  No clinical abnormalities were observed in intraocular pressure or pupil diameter in subjects receiving sildenafil. Currently, no evidence suggests that long-term treatment with sildenafil has an effect on intraocular pressure or is associated with the development or worsening of glaucoma.
authors.affiliation: Kaiyo Clinic, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yajima
authors.forename: Y
authors.initials: Y
authors.lastname: Yajima
authors.forename: N
authors.initials: N
authors.lastname: Koppiker
authors.forename: J E
authors.initials: JE
authors.lastname: Grunwald
authors.forename: A M
authors.initials: AM
authors.lastname: Laties
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy; D005901:Glaucoma / Q000150:complications; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D011680:Pupil / Q000187:drug effects; D011687:Purines; D000068677:Sildenafil Citrate; D016037:Single-Blind Method; D013450:Sulfones; D014065:Tonometry, Ocular
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases